Management of COVID-19 patients experiencing persisting respiratory failure despite corticosteroids remains challenging. Data on high-dose intravenous anakinra (HD-ANK) in this context are lacking. We aimed to investigate the impact of HD-ANK on mortality in COVID-19 patients progressing to non-invasive ventilation (NIV) while receiving corticosteroids. We retrospectively analyzed the impact of HD-ANK on 28-day mortality in individuals hospitalized with COVID-19 necessitating NIV after corticosteroid initiation. A total of 256 patients were identified: 146 received standard-of-care only (SOC), and 110 received HD-ANK+SOC. The groups were well-balanced at baseline. In-hospital mortality at 28 days did not differ between the two groups. HD-ANK is not beneficial in patients with severe COVID-19 deteriorating despite corticosteroids.

High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation / Mastrangelo, Andrea; Monardo, Roberta; Galli, Laura; Tomelleri, Alessandro; Tassan Din, Chiara; Canetti, Diana; Messina, Emanuela; Guffanti, Monica; Danise, Anna; Campochiaro, Corrado; Cavalli, Giulio; Monti, Giacomo; Cinque, Paola; Scarpellini, Paolo; Landoni, Giovanni; Ciceri, Fabio; Dagna, Lorenzo; Castagna, Antonella; Ripa, Marco. - In: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. - ISSN 0934-9723. - 42:11(2023), pp. 1383-1387. [10.1007/s10096-023-04661-2]

High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation

Mastrangelo, Andrea
Primo
;
Monardo, Roberta
Secondo
;
Tomelleri, Alessandro;Canetti, Diana;Messina, Emanuela;Campochiaro, Corrado;Cavalli, Giulio;Monti, Giacomo;Landoni, Giovanni;Ciceri, Fabio;Dagna, Lorenzo;Castagna, Antonella
Penultimo
;
Ripa, Marco
Ultimo
2023-01-01

Abstract

Management of COVID-19 patients experiencing persisting respiratory failure despite corticosteroids remains challenging. Data on high-dose intravenous anakinra (HD-ANK) in this context are lacking. We aimed to investigate the impact of HD-ANK on mortality in COVID-19 patients progressing to non-invasive ventilation (NIV) while receiving corticosteroids. We retrospectively analyzed the impact of HD-ANK on 28-day mortality in individuals hospitalized with COVID-19 necessitating NIV after corticosteroid initiation. A total of 256 patients were identified: 146 received standard-of-care only (SOC), and 110 received HD-ANK+SOC. The groups were well-balanced at baseline. In-hospital mortality at 28 days did not differ between the two groups. HD-ANK is not beneficial in patients with severe COVID-19 deteriorating despite corticosteroids.
2023
COVID-19
Interleukin 1 receptor antagonist protein
Noninvasive ventilation
File in questo prodotto:
File Dimensione Formato  
s10096-023-04661-2.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Copyright dell'editore
Dimensione 372.27 kB
Formato Adobe PDF
372.27 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/151316
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact